the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).
Colorectal cancer with RAS mutation (KRAS or NRAS)
Colorectal liver metastases (single or multiple)
Planned R0 resection of liver metastases (and primary tumor, if present)
Anatomical and non-anatomical liver resection technically feasible
Extrahepatic metastases
Planned staged liver resection (e.g. two-stage hepatectomy)
Diagnosis of another cancer < 5 years prior to randomization Exceptions: curatively treated in situ cervical cancer, curatively resected non-melanoma skin cancer
Expected lack of compliance
Technische Universität Dresden
Lead sponsor
German Cancer Research Center
Collaborator